Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently the focus of a securities class action lawsuit following a dramatic collapse in share price earlier this year. The litigation centers on the company’s lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). According to the allegations, Capricor and certain executives made materially misleading statements regarding clinical trial data and the regulatory pathway for Deramiocel. Specifically, plaintiffs allege that the company adopted changes to its pre-specified statistical analysis plan (SAP) without obtaining the necessary agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA). The forensic core of the complaint hinges on the timing of disclosures. On December 3, 2025, Capricor announced positive topline results for its Phase 3 HOPE-3 study, sending shares surging 370%. Following this, the company conducted a public stock offering of 6 million shares at $25 per share. However, in July 2026, FDA briefing documents revealed the previously undisclosed SAP changes, triggering a 64% collapse in the company’s share price. The deadline for affected investors to seek appointment as lead plaintiff in this class action was September 28, 2026. This case serves as a poignant reminder of the risks associated with biotechnology firms that prioritize rapid capital raises following initial clinical data releases, particularly when that data is subject to evolving or disputed regulatory standards. ## Key Takeaways - Capricor Therapeutics faces litigation over alleged undisclosed changes to its statistical analysis plan for Deramiocel. - The company conducted a major stock offering following positive trial results, only for shares to collapse after FDA documents revealed regulatory discrepancies. - The case highlights the forensic importance of verifying regulatory alignment in biotech clinical trial reporting. ## Sources - Newsfile Corp — Summary of investor class action lawsuit and regulatory allegations against Capricor Therapeutics, September 27, 2026.
Original reporting by Newsfile Corp. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
